Binder and fusion protein targeting pcna, and uses thereof

Abstract

The present disclosure provides a binder that specifically targets the PCNA protein, a fusion protein comprising the same, and uses thereof, which belong to the field of biotechnology. In the present disclosure, artificial intelligence technology is employed to design binders that specifically target PCNA. The resulting binders exhibit good specificity and high affinity, and are capable of efficiently binding to the PCNA antigen. Further, fusion proteins are prepared by fusing the aforementioned binders to an RBCC domain or a mutant thereof, or by directly fusing the aforementioned binders to an Fc fragment. The fusion proteins can specifically bind to the target protein via their binder domain, thereby initiating a protein degradation pathway to achieve targeted degradation of the PCNA protein, and they can also activate intracellular p53, inducing its phosphorylation to prevent ubiquitination-mediated degradation by ubiquitin ligases such as MDM2, thus giving the present disclosure substantial clinical application value.

Dependencies are inferred from the claim text.